These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20872033)

  • 21. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
    Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
    Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
    Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study.
    Kania K; Pawlak MA; Forycka M; Wiłkość-Dębczyńska M; Michalak S; Łukaszewska A; Wyciszkiewicz A; Wypych A; Serafin Z; Marcinkowska J; Kozubski W; Kalinowska-Łyszczarz A
    Neurol Neurochir Pol; 2024; 58(2):176-184. PubMed ID: 38324117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
    Laroni A; Gandoglia I; Solaro C; Ribizzi G; Tassinari T; Pizzorno M; Parodi S; Baldassarre G; Rilla MT; Venturi S; Capello E; Sormani MP; Uccelli A; Mancardi GL
    BMC Neurol; 2014 May; 14():103. PubMed ID: 24885703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait.
    Alroughani R; Al Hashel J; Thussu A; Ahmed SF
    Med Princ Pract; 2013; 22(5):495-9. PubMed ID: 23797019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is natalizumab a breakthrough in the treatment of multiple sclerosis?
    Doggrell SA
    Expert Opin Pharmacother; 2003 Jun; 4(6):999-1001. PubMed ID: 12783595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Information processing speed and influential factors in multiple sclerosis].
    Zhang ML; Xu EH; Dong HQ; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?
    Novotna K; Rusz J; Kubala Havrdova E; Lizrova Preiningerova J
    J Neural Transm (Vienna); 2019 Jun; 126(6):731-737. PubMed ID: 31098724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab efficacy on cognitive impairment in MS.
    Mattioli F; Stampatori C; Bellomi F; Capra R
    Neurol Sci; 2011 Jan; 31 Suppl 3():321-3. PubMed ID: 20535512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
    J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.